A single-dose pharmacokinetic (PK) study of lasofoxifene in healthy volunteers and subjects with mild or moderate hepatic impairment

被引：0
|
作者：
Bramson, C
Ouellet, D
Roman, D
Randinitis, E
Gardner, MJ
机构：
[1] Pfizer Inc, Ann Arbor, MI USA
[2] Pfizer Inc, Groton, CT 06340 USA
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2004年 / 44卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
19
引用
收藏
页码：1189 / 1189
页数：1
相关论文
共 50 条
  • [41] Single-dose pharmacokinetics of lycopene in healthy volunteers
    Rodvold, K. A.
    [J]. CHEMICO-BIOLOGICAL INTERACTIONS, 2006, 161 (03) : 194 - 195
  • [42] Effect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers
    Robertson, P
    Hellriegel, ET
    Arora, S
    Nelson, M
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (02): : 205 - 214
  • [43] Single-Dose Pharmacokinetics, Safety, and Tolerability of Avadomide (CC-122) in Subjects With Mild, Moderate, or Severe Renal Impairment
    Li, Yan
    MacGorman, Kimberly
    Liu, Liangang
    Chen, Jian
    Hoffmann, Matthew
    Palmisano, Maria
    Zhou, Simon
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (07): : 785 - 796
  • [44] Pharmacokinetics and Safety Evaluation of Single-Dose Saroglitazar Magnesium in Subjects with Hepatic Impairment
    Lawitz, Eric
    Parmar, Deven
    Momin, Taufik
    Shaikh, Farheen
    Patel, Harilal
    Hayes, Helen
    Swint, Kimberly
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (12): : 1142 - 1155
  • [45] Pharmacokinetics (PK), Safety, and Tolerability of Etrasimod (APD334) in Participants With Mild, Moderate, or Severe Hepatic Impairment: A Single-Dose, Open-Label, Parallel-Group Study
    Lee, Caroline
    Tang, Yong
    Schroeder, Cassandra
    Zhang, Jinkun
    Nguyen-Cleary, Thai
    Ma, Michael
    Lyon, Naomi
    Grundy, John S.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S327 - S328
  • [46] Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
    David Schnell
    Susanne Buschke
    Holger Fuchs
    Dietmar Gansser
    Rainer-Georg Goeldner
    Martina Uttenreuther-Fischer
    Peter Stopfer
    Sven Wind
    Marc Petersen-Sylla
    Atef Halabi
    Rüdiger Koenen
    [J]. Cancer Chemotherapy and Pharmacology, 2014, 74 : 267 - 275
  • [47] Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
    Schnell, David
    Buschke, Susanne
    Fuchs, Holger
    Gansser, Dietmar
    Goeldner, Rainer-Georg
    Uttenreuther-Fischer, Martina
    Stopfer, Peter
    Wind, Sven
    Petersen-Sylla, Marc
    Halabi, Atef
    Koenen, Ruediger
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (02) : 267 - 275
  • [48] Pharmacokinetics (PK) of garenoxacin in healthy subjects and in subjects with hepatic impairment.
    Noveck, RJ
    Vargas, R
    Russo, R
    Bello, A
    Gajjar, D
    Grasela, D
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P79 - P79
  • [49] SINGLE-DOSE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF THE DUAL ENDOTHELIN RECEPTOR ANTAGONIST APROCITENTAN IN SUBJECTS WITH MODERATE HEPATIC IMPAIRMENT.
    Fontes, M.
    Halabi, A.
    Tomaszewska-Kiecana, M.
    Dinge-Manse, J.
    Sidharta, P.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S47 - S48
  • [50] Pharmacokinetics, safety, and tolerability of etrasimod (APD334) in subjects with mild, moderate, or severe hepatic impairment: a single-dose, open-label, parallel-group study
    Lee, C.
    Tang, Y.
    Schroeder, C.
    Zhang, J.
    Nguyen-Cleary, T.
    Mullin, S.
    Ma, M.
    Lyon, N.
    Grundy, J.
    [J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S321 - S322
12345